Document is current
Any future updates will be listed below
-
Authors
Gillies, Taryn E
Pargett, Michael
Silva, Jillian M
Teragawa, Carolyn K
McCormick, Frank
Albeck, John G https://orcid.org/0000-0003-2688-8653
-
Funding
Funding for this research was provided by:
HHS | NIH | National Cancer Institute (1R35CA197709)
HHS | NIH | National Cancer Institute (P30CA093373)
HHS | NIH | National Cancer Institute (K01CA197138)
HHS | NIH | National Institute of General Medical Sciences (1R01GM115650)
U.S. Department of Defense (W81XWH‐16-1-0085)
- License Information
-
More Information
Article History
Received: 17 February 2020
Revised: 2 September 2020
Accepted: 21 September 2020
First Online: 19 October 2020
Conflict of interest
: The authors acknowledge the following potential sources for conflicts of interest. Frank McCormick is a consultant for the following companies: Aduro Biotech, Amgen, Daiichi Ltd., Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, Inc., PellePharm, Pfizer Inc., PMV Pharma, Portola Pharmaceuticals, and Quanta Therapeutics. Dr. McCormick has received research grants from Daiichi Sankyo Ltd. and is a recipient of funded research from Gilead Sciences. Dr. McCormick is a consultant and co‐founder for the following companies (with ownership interest including stock options): BridgeBio, DNAtrix Inc., Olema Pharmaceuticals, Inc., and Quartz. Dr. McCormick is Scientific Director of the NCI Ras Initiative at Frederick National Laboratory for Cancer Research/Leidos Biomedical Research Inc. John Albeck has received research grants from Kirin Corporation.
